Development and clinical validation of a quantitative mass spectrometric assay for PD-L1 protein in FFPE NSCLC samples

被引：0

作者：

An, E. ^{[1
]}

Liao, W. ^{[1
]}

Thyparambil, S. ^{[1
]}

Rodriguez, J. ^{[2
]}

Salgia, R. ^{[3
]}

Wistuba, I. ^{[2
]}

Burrows, J. ^{[1
]}

Hembrough, T. ^{[1
]}

机构：

[1] OncoPlex Diagnost, Rockville, MD USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Chicago, Chicago, IL 60637 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷

关键词：

D O I：

10.1016/S0959-8049(14)70615-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

489

引用

页码：159 / 159

页数：1

共 50 条

[41] Analytical validation and clinical utility of an immunohistochemical PD-L1 diagnostic assay for treatment with durvalumab in urothelial carcinoma patients
Zajac, M.
Boothman, A. M.
Ben, Y.
Gupta, A.
Antal, J.
Jin, X.
Nielsen, A.
Manriquez, G.
Barker, C.
Wang, P.
Patil, P.
Schechter, N.
Rebelatto, M.
Walker, J.
CANCER RESEARCH, 2017, 77
[42] Development and validation of a liquid chromatography-tandem mass spectrometric assay for quantitative analyses of triptans in hair
Vandelli, Daniele
Palazzoli, Federica
Verri, Patrizia
Rustichelli, Cecilia
Marchesi, Filippo
Ferrari, Anna
Baraldi, Carlo
Giuliani, Enrico
Licata, Manuela
Silingardi, Enrico
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2016, 1017 : 136 - 144
[43] Assessment of PD-L1 Expression in Cytology Samples: An Anlaysis of 263 Consecutive NSCLC Biopsies.
Illei, P.
Rajgariah, A.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S948 - S948
[44] Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples
Casadevall, David
Clave, Sergi
Taus, Alvaro
Hardy-Werbin, Max
Rocha, Pedro
Lorenzo, Marta
Menendez, Silvia
Salido, Marta
Albanell, Joan
Pijuan, Lara
Arriola, Edurne
CLINICAL LUNG CANCER, 2017, 18 (06) : 682 - +
[45] The SP142 PD-L1 IHC assay for atezolizumab (atezo) reflects pre-existing immune status in NSCLC and correlates with PD-L1 mRNA
Williams, J.
Kowanetz, M.
Koeppen, H.
Boyd, Z.
Kadel, E. E., III
Smith, D.
McCleland, M.
Zou, W.
Hegde, P. S.
ANNALS OF ONCOLOGY, 2016, 27
[46] Development of a Non-IgG PD-1/PD-L1 Inhibitor by in Silico Mutagenesis and an In-Cell Protein-Protein Interaction Assay
Ning, Boyang
Ren, Xueli
Hagiwara, Kyoji
Takeoka, Shinji
Ito, Yoshihiro
Miyatake, Hideyuki
ACS CHEMICAL BIOLOGY, 2021, 16 (02) : 316 - 323
[47] Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC with High PD-L1 Expression Tested on Cytology Versus Biopsy Samples
Guo, K.
Kasymjanova, G.
Wang, H.
Sakr, L.
Small, D.
Cohen, V.
Pepe, C.
Spatz, A.
Agulnik, J.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S531 - S531
[48] Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma
Morales-Betanzos, Carlos A.
Lee, Hyoungjoo
Ericsson, Paula I. Gonzalez
Balko, Justin M.
Johnson, Douglas B.
Zimmerman, Lisa J.
Liebler, Daniel C.
MOLECULAR & CELLULAR PROTEOMICS, 2017, 16 (10) : 1705 - 1717
[49] Quantitative continuous scoring of PD-L1 for superior patient selection for anti-PD-L1 treatment of locally advanced or unresectable NSCLC
Lesniak, Jan Martin
Bisha, Ina
Christ, Simon
Meinecke, Lina
Padel, Thomas
Monasor, Laura Sebastian
Sontakke, Pallavi
Tan, Tze Heng
Medrikova, Dasa
Storti, Andrea
Shumilov, Anatoliy
Sade, Hadassah
Schmidt, Gunter
Stewart, Ross
Shrestha, Yashaswi
CANCER RESEARCH, 2024, 84 (06)
[50] Development of a clinical trial assay for PD-L1 immunohistochemistry (IHC) for use with pembrolizumab (pembro) clinical trials in melanoma.
Dolled-Filhart, Marisa
Ebbinghaus, Scot
Roach, Charlotte
Ponto, Gary
Toland, Grant
Jansson, Malinka
Emancipator, Kenneth
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →